

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
1	BRS	L1	23	His-phe-Arg-Trp	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 12:37			0
2	BRS	L2	10	His-D-phe-Arg-Trp	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 12:37			0
3	BRS	L3	3252	cyclic adj peptide	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 12:37			0
4	BRS	L4	2	(1 or 2) same 3	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 12:39			0
5	BRS	L5	4	composition same (1 or 2)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 12:42			0
6	BRS	L6	269	sexual adj response	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 12:42			0
7	BRS	L7	3	(1 or 2) same 6	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 12:43			0
8	BRS	L8	327	melanocortin adj receptor	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 12:45			0
9	BRS	L9	3	melanocortin adj receptor adj specific adj peptide	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 12:46			0
10	BRS	L10	389	alpha-MSH	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 12:47			0
11	BRS	L11	137	10 same (fragment or analog)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 12:47			0
12	BRS	L12	3018	sexual adj dysfunction	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 12:48			0
13	BRS	L13	10	(6 or 12) same (1 or 2 or 11)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 12:50			0
14	BRS	L14	3	blood adj christine.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 12:51			0
15	BRS	L15	4	shadiack adj annette.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 12:51			0
16	BRS	L16	2	bernstein adj joanna.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 12:52			0

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
17	BRS	L17	2	herbert adj guy.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 12:52			0
18	BRS	L18	5	(14 or 15 or 16 or 17)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 12:53			0
19	BRS	L19	2	(14 or 15 or 16 or 17) and (1 or 2)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 12:53			0
20	BRS	L20	24	1 or 2	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 13:06			0
21	BRS	L21	2	6051555.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 13:07			0

\$

FILE 'MEDLINE' ENTERED AT 13:30:55 ON 13 SEP 2003

FILE 'CAPLUS' ENTERED AT 13:30:55 ON 13 SEP 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 13:30:55 ON 13 SEP 2003

COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 13:30:55 ON 13 SEP 2003

COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 13:30:55 ON 13 SEP 2003

COPYRIGHT 2003 THOMSON ISI

FILE 'AGRICOLA' ENTERED AT 13:30:55 ON 13 SEP 2003

=> s His-Phe-arg-Trp-oh

L1 1 HIS-PHE-ARG-TRP-OH

=> d 11 1 ibib abs

L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1977:439803 CAPLUS

DOCUMENT NUMBER: 87:39803

TITLE: Des-N.alpha.1-acetyl-.alpha.-melanotropin. A synthetic substrate for specific N-terminal directed enzymic acetylation

AUTHOR(S): Smeets, Paul; Granger, Michele; Van Nispen, Johannes W.; Bloemendal, Hans; Tesser, Godefridus I.

CORPORATE SOURCE: Dep. Org. Chem., Cathol. Univ. Nijmegen, Nijmegen, Neth.

SOURCE: International Journal of Peptide & Protein Research (1977), 9(1), 52-6

CODEN: IJPPC3; ISSN: 0367-8377

DOCUMENT TYPE: Journal

LANGUAGE: English

AB R-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 (I, R = H), deacetyl-MSH, was prepd. by coupling BOC-Ser-Tyr-Ser-Met-Glu(OCMe3)-***His*** - ***Phe*** - ***Arg*** - ***Trp*** - ***OH*** (BOC = Me3CO2C) to H-Lys(Msc)-Pro-Val-NH2 (II, Msc = MeSO2CH2CH2O2C) with dicyclohexylcarbodiimide and deblocking the resulting protected tridecapeptide amide with CF3CO2H for BOC and CMe3 groups and NaOH for the Msc group. BOC-Lys(Msc)-OC6H4NO2-4 was prepd. and coupled to H-Pro-Val-NH2 to give BOC-Lys(Msc)-Pro-Val-NH2, which was BOC-deblocked with HCl to give II. I (R = H) was selectively acetylated at the N-terminal NH2 by an enzyme system in a cell-free ext. of calf eye lenses to give I (R = AC) (.alpha.-MSH). The latter was prepd., but was not acetylated at the side chain NH2 by the above enzyme system. R1-Ser-Tyr-Ser-Met-Glu(OR2)-His-Phe-Arg-Trp-Gly-Lys(R3)-Pro-Val-NH2 (R1 = R2 = H, R3 = Msc, Ac; R1 = Ac, R2 = H, R3 = Msc, Ac; R1 = BOC, R2 = CMe3, R3 = H, Ac) were also prepd.

=> s his-D-phe-arg-trp-oh

L2 0 HIS-D-PHE-ARG-TRP-OH

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

26.25

26.46

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.65

-0.65

STN INTERNATIONAL LOGOFF AT 13:32:51 ON 13 SEP 2003

FILE 'MEDLINE' ENTERED AT 13:15:17 ON 13 SEP 2003

FILE 'CAPLUS' ENTERED AT 13:15:17 ON 13 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 13:15:17 ON 13 SEP 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 13:15:17 ON 13 SEP 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 13:15:17 ON 13 SEP 2003
COPYRIGHT 2003 THOMSON ISI

FILE 'AGRICOLA' ENTERED AT 13:15:17 ON 13 SEP 2003

=> s His-Phe-Arg-Trp
L1 411 HIS-PHE-ARG-TRP

=> s His-D-phe-Arg-Trp
L2 73 HIS-D-PHE-ARG-TRP

=> s l1 or l2
L3 462 L1 OR L2

=> s composition (p) l3
L4 20 COMPOSITION (P) L3

=> duplicateremove l4
ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove l4
'REMOVE L28' IS NOT VALID HERE
Enter "REMOVE" to identify and remove duplicate answers.
Enter "IDENTIFY" to identify duplicate answers in the answer set.
Enter "ONLY" to identify and create an answer set containing only
duplicate records.
ENTER REMOVE, IDENTIFY, ONLY, OR (?):duplicate remove
'DUPLICATE REMOVE' IS NOT VALID HERE
Enter "REMOVE" to identify and remove duplicate answers.
Enter "IDENTIFY" to identify duplicate answers in the answer set.
Enter "ONLY" to identify and create an answer set containing only
duplicate records.
ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove
DUPLICATE PREFERENCE IS 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L4
L5 9 DUPLICATE REMOVE L4 (11 DUPLICATES REMOVED)

=> d l5 1-9 ibib abs

L5 ANSWER 1 OF 9 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 2003:323715 BIOSIS
DOCUMENT NUMBER: PREV200300323715
TITLE: Compositions and methods for treatment of sexual
dysfunction.
AUTHOR(S): Blood, Christine H.; Shadiack, Annette M. (1); Bernstein,
Joanna K.; Herbert, Guy H.
CORPORATE SOURCE: (1) Somerset, NJ, USA USA
ASSIGNEE: Palatin Technologies, Inc., Cranbury, NJ, USA
PATENT INFORMATION: US 6579968 June 17, 2003
SOURCE: Official Gazette of the United States Patent and Trademark
Office Patents, (June 17 2003) Vol. 1271, No. 3, pp. No
Pageination. <http://www.uspto.gov/web/menu/patdata.html>.
e-file.
ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English

AB ***Compositions*** and methods are provided for treatment of sexual
dysfunction in mammals, including male sexual dysfunction, such as
erectile dysfunction, and female sexual dysfunction. In one embodiment, a
peptide-based ***composition*** including the peptide sequence
Ac-Nle-cyclo(-Asp- ***His*** - ***D*** - ***Phe*** - ***Arg*** -
Trp -Lys)-OH is administered. Methods of administration include
injection, oral, nasal and mucosal administration.

L5 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:595493 CAPLUS
DOCUMENT NUMBER: 137:145614
TITLE: Pharmaceutical compositions containing a peptide for
treatment of sexual dysfunction
INVENTOR(S): Blood, Christine H.; Shadiack, Annette M.; Bernstein,
Joanna K.; Herbert, Guy H.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 20 pp., Cont.-in-part of U.S.
Ser. No. 606,501.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002107182	A1	20020808	US 2002-40547	20020104
US 6579968	B1	20030617	US 2000-606501	20000628
PRIORITY APPLN. INFO.:			US 1999-142346P P	19990629
			US 2000-194987P P	20000405
			US 2000-606501 A2	20000628

AB ***Compns*** . and methods are provided for treatment of sexual
dysfunction in mammals, including male sexual dysfunction, such as
erectile dysfunction, and female sexual dysfunction. In one embodiment, a
peptide-based ***compn*** . including the peptide sequence
Ac-Nle-cyclo(-Asp- ***His*** - ***D*** - ***Phe*** - ***Arg*** -
Trp -Lys)-OH (I) is administered. Methods of administration
include injection, oral, nasal and mucosal administration. I was
dissolved in a 50 mM citrate, pH approx. 6.0, at a concn. of .825 mg per
mL to obtain a nasal soln. Nasal administration of I at a concn. of 25
.mu.k/kg induced 100% penile erection in rats for 2 times in 30 min.

L5 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:12284 CAPLUS
DOCUMENT NUMBER: 134:76409
TITLE: Compositions and methods for treatment of sexual
dysfunction
INVENTOR(S): Blood, Christine H.; Shadiack, Annette M.; Bernstein,
Joanna K.; Herbert, Guy W.
PATENT ASSIGNEE(S): Palatin Technologies Inc., USA
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000224	A1	20010104	WO 2000-US18217	20000629
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,				
CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,				
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,				
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,				
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,				
AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,				
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6579968	B1	20030617	US 2000-606501	20000628
BR 2000012200	A	20020326	BR 2000-12200	20000629
EP 1196184	A1	20020417	EP 2000-950283	20000629
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO				
JP 2003503357	T2	20030128	JP 2001-505933	20000629
PRIORITY APPLN. INFO.:			US 1999-142346P P	19990629
			US 2000-194987P P	20000405
			US 2000-606501 A	20000628
			WO 2000-US18217 W	20000629

AB ***Compns*** . and methods are provided for the treatment of sexual
dysfunctions in mammals, such as erectile dysfunction and female sexual
dysfunction. In one embodiment, a peptide-based ***compn*** .
including the peptide sequence Ac-Nle-cyclo(-Asp- ***His*** - ***D***
- ***Phe*** - ***Arg*** - ***Trp*** -Lys)-OH is administered.
Methods of administration include injection, oral, nasal and mucosal

administration.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 9 MEDLINE on STN DUPLICATE 1
ACCESSION NUMBER: 92270473 MEDLINE
DOCUMENT NUMBER: 92270473 PubMed ID: 1667689
TITLE: Detection of a novel sequence change in the major form of alpha-MSH isolated from the intermediate pituitary of the reptile, *Anolis carolinensis*.
AUTHOR: Dorez R M; Lancha A; Rand-Weaver M; Jankelow L; Adamczyk D L
CORPORATE SOURCE: University of Denver, Department of Biological Sciences, CO 80208.
CONTRACT NUMBER: RR06565 (NCRR)
SOURCE: PEPTIDES, (1991 Nov-Dec) 12 (6) 1261-6.
Journal code: 8008690. ISSN: 0196-9781.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199206
ENTRY DATE: Entered STN: 19920710
Last Updated on STN: 19920710
Entered Medline: 19920622

AB Intermediate pituitaries of the reptile, *Anolis carolinensis*, were separately pulse labeled with [3H]Trp and [3H]Tyr. The major form of alpha-MSH was purified by immunoprecipitation and isolated by reverse phase HPLC. Tryptic peptide analysis indicated that the [3H]Trp-labeled C-terminal fragment of *Anolis* alpha-MSH had the same retention time as mammalian ACTH(9-13) amide; however, the [3H]Tyr-labeled N-terminal fragment did not coelute with either mammalian ACTH(1-8) or N-acetyl-ACTH(1-8). Purification of alpha-MSH from 76 *Anolis* intermediate pituitaries confirmed that a sequence change had occurred in the N-terminal region of *Anolis* alpha-MSH. The tissues were acid extracted and purified by Sephadex G-25 chromatography and reverse phase HPLC to yield 4.5 micrograms of purified *Anolis* alpha-MSH for amino acid ***composition*** analysis and automated Edman degradation sequence analysis. The major form of *Anolis* alpha-MSH is nonacetylated and has the following novel primary sequence: Ser-Tyr-Ala-Met-Glu- ***His*** - ***Phe*** - ***Arg*** - ***Trp*** - Gly-Lys-Pro(Val-amide). The presence of Val-amide was verified by immunological analysis, tryptic peptide analysis and amino acid ***composition*** analysis.

L5 ANSWER 5 OF 9 MEDLINE on STN DUPLICATE 2
ACCESSION NUMBER: 91348465 MEDLINE
DOCUMENT NUMBER: 91348465 PubMed ID: 1652532
TITLE: Characterization of chicken ACTH and alpha-MSH: the primary sequence of chicken ACTH is more similar to *Xenopus* ACTH than to other avian ACTH.
AUTHOR: Hayashi H; Imai K; Imai K
CORPORATE SOURCE: Department of Protein Chemistry, Faculty of General Studies, Gunma University, Maebashi, Japan.
SOURCE: GENERAL AND COMPARATIVE ENDOCRINOLOGY, (1991 Jun) 82 (3) 434-43.
Journal code: 0370735. ISSN: 0016-6480.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199110
ENTRY DATE: Entered STN: 19911020
Last Updated on STN: 19911020
Entered Medline: 19911003

AB Adrenocorticotrophic (ACTH) and melanocyte stimulating (MSH) hormones have been demonstrated in the same cells in the cephalic half of the pars distalis of the chicken pituitary glands in three ways: (I) immunohistochemistry, (II) radioimmunoassay (RIA) using both anti-human or porcine ACTH and synthetic alpha-MSH antibodies, and (III) isolation and purification, followed by the determination of amino acid ***compositions*** of both hormones. The contents of ACTH and alpha-MSH are estimated by RIA to be 1600 and 10 ng/gland, respectively. ACTH missed 1 (des-Phe39-ACTH) or 2 residues (des-Glu38, Phe39-ACTH) from the C-terminal portion was also isolated. The recoveries of these ACTHs are differed from preparation to preparation. The complete amino acid sequence of chicken ACTH (39 residues) has been determined as NH2-Ser-Tyr-Ser-Met-Glu- ***His*** - ***Phe*** - ***Arg*** -

Trp -Gly-Lys-Pro-Val-Gly-Arg-Lys-Arg- Arg- Pro-Ile-Lys-Val-Tyr-Pro-Asn-Gly-Val-Asp-Glu-Ser-Ala-Glu-Ser-Tyr-Pro- Met-Glu-Phe-OH Strikingly the amino acid sequence of chicken ACTH shows a closer resemblance to that from an amphibian, Xenopus (3 residue substitution) than that from another bird, the ostrich (7 residue substitution) or the turkey (at least 9 residue substitution).

L5 ANSWER 6 OF 9 MEDLINE on STN DUPLICATE 3
 ACCESSION NUMBER: 90013917 MEDLINE
 DOCUMENT NUMBER: 90013917 PubMed ID: 2552247
 TITLE: Melanin concentrating hormone. V. Isolation and characterization of alpha-melanocyte-stimulating hormone from frog pituitary glands.
 AUTHOR: Tonon M C; Desrues L; Lazure C; Jenks B G; Chretien M; Vaudry H
 CORPORATE SOURCE: URA CNRS 650, Unite Affiliee a l'INSERM, Universite de Rouen, Mont-Saint-Aignan, France.
 SOURCE: LIFE SCIENCES, (1989) 45 (13) 1155-61.
 Journal code: 0375521. ISSN: 0024-3205.
 PUB. COUNTRY: ENGLAND: United Kingdom
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 198911
 ENTRY DATE: Entered STN: 19900328
 Last Updated on STN: 19900328
 Entered Medline: 19891109

AB The structure of alpha-melanocyte-stimulating hormone (alpha-MSH) has been determined in the pars intermedia of the frog Rana ridibunda. Pulse-chase labeling of frog neurointermediate lobes with selective amino acids revealed that the ***composition*** of frog alpha-MSH is similar to that of alpha-MSH from all mammalian species yet studied. Tryptic mapping of nexly synthesized alpha-MSH generated two fragments with the following amino acid ***composition*** : (T1) Trp, Pro, Lys, Gly, Val and (T2) Tyr, Arg, Phe, His, Ser, Glu. Concurrently, alpha-MSH was purified from 100 neurointermediate lobes to apparent homogeneity by reverse-phase HPLC. The sequence of the peptide determined by automated Edman degradation was Ser-Tyr-Ser-Met-Glu- ***His*** - ***Phe*** - ***Arg*** - ***Trp*** -Gly-Lys-Pro-Val. The structure of frog alpha-MSH is thus identical to mammalian des-N alpha-acetyl alpha-MSH and differs from the sequence of toad (Xenopus laevis) alpha-MSH only by the first residue (Ser instead of Ala). These results confirm that the sequence of alpha-MSH has been highly preserved during evolution.

L5 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1989:19047 CAPLUS
 DOCUMENT NUMBER: 110:19047
 TITLE: Use of melanotropin or its peptide fragments for the treatment of asthmatic and allergic diseases
 INVENTOR(S): Aderhold, Dieter
 PATENT ASSIGNEE(S): Fed. Rep. Ger.
 SOURCE: Ger. Offen., 3 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3623019	A1	19880121	DE 1986-3623019	19860709
PRIORITY APPLN. INFO.:			DE 1986-3623019	19860709

AB .alpha.-MSH, .beta.-MSH, .gamma.-MSH, and/or their peptide fragments are useful for the treatment of allergic or asthmatic diseases. A dermally applied ***compn*** contained 2 mg melanotropin tetrapeptide (***His*** - ***Phe*** - ***Arg*** - ***Trp***) colloiddally adsorbed to 12 mg Al(OH)₃, a swell as 13 mL water and 7 mL EtOH. This ***compn*** was applied to the nostrils and the areas over the sinuses and >90% of the patients showed a decrease in the symptoms related to hay fever and dust allergies.

L5 ANSWER 8 OF 9 MEDLINE on STN DUPLICATE 4
 ACCESSION NUMBER: 81133559 MEDLINE
 DOCUMENT NUMBER: 81133559 PubMed ID: 7470089
 TITLE: Purification and characterization of a gamma-melanotropin precursor from frozen human pituitary glands.
 AUTHOR: Estivariz F E; Hope J; McLean C; Lowry P J

SOURCE: BIOCHEMICAL JOURNAL, (1980 Oct 1) 191 (1) 125-32.
 Journal code: 2984726R. ISSN: 0264-6021.
 PUB. COUNTRY: ENGLAND: United Kingdom
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 198104
 ENTRY DATE: Entered STN: 19900316
 Last Updated on STN: 19900316
 Entered Medline: 19810413

AB A new melanocyte-stimulating peptide has been isolated from acid extracts of frozen human pituitary glands by salt/ethanol fractionation, Sephadex G-75 gel filtration and DEAE- and CM-cellulose ion-exchange chromatography. The peptide is glycosylated, has an N-terminal tryptophan residue and an apparent mol.wt. of 16000 as estimated by sodium dodecyl sulphate/polyacrylamide-gel electrophoresis. Its amino acid analysis closely resembles residues Trp-105 to Gln-29 predicted for the common precursor protein of bovine corticotropin and beta-lipotropin by Nakanishi, Inoue, Kita, Nakamura, Chang, Cohen & Numa [(1979) Nature (London) 278, 423-427]. This fragment is expected to have melanotropin activity due to the tetrapeptide - ***His*** - ***Phe*** - ***Arg*** - ***Trp*** - (residues -51 to -48) of the predicted sequence of the common precursor. It was found to have a molar potency of 1×10^{-5} relative to alpha-melanotropin in the frog skin bioassay. These characteristics are consistent with the isolated melanotropin peptide being a non-corticotropin, non-lipotropin peptide of the human common precursor protein of corticotropin and lipotropin. The peptide neither potentiates the adrenal weight-maintenance activity of corticotropin-(1-24)-tetracosapeptide when administered to hypophysectomized rats, nor stimulates release of non-esterified fatty acids from isolated rat epididymal cells. A second N-terminal-tryptophan glycopeptide was also isolated, which had an amino-acid ***composition*** similar to that predicted for the bovine common precursor protein, residues Trp-105 to Gly-35.

L5 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1972:46519 CAPLUS
 DOCUMENT NUMBER: 76:46519
 TITLE: .beta.-Ala1-Lys17,18-.beta.1-18-corticotropin-Lys18-amide
 INVENTOR(S): Rittel, Werner
 PATENT ASSIGNEE(S): CIBA-Geigy A.-G.
 SOURCE: Ger. Offen., 25 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2124549	A	19711209	DE 1971-2124549	19710518
CH 549554	A	19740531	CH 1970-7836	19700527
US 3794632	A	19740226	US 1971-145032	19710519
NL 7107260	A	19711130	NL 1971-7260	19710526
FR 2100693	A1	19720324	FR 1971-19262	19710527
FR 2100693	A5	19720324		
HU 164014	P	19731228	HU 1971-CI1119	19710527
			CH 1970-7836	19700527

PRIORITY APPLN. INFO.:

AB The title compd., H-.beta.-Ala-Tyr-Ser-Met-Glu- ***His*** - ***Phe*** - ***Arg*** - ***Trp*** -Gly-Lys-Pro-Val-Gly-Lys-Lys-Lys-Lys-NH2 (I), with prolonged adrenocorticotrophic activity was prepd. by reaction of Boc-.beta.-Ala-Tyr-Ser-Met-Glu(OBu-tert)- ***His*** - ***Phe*** - ***Arg*** - ***Trp*** -Gly-OH.4H2O (Boc=CO2Bu-tert) with H-Lys(Boc)-Pro-Val-Gly-Lys(Boc)-Lys(Boc)-Lys(Boc)-Lys(Boc)-NH2 in the presence of N HCl, N-hydroxysuccinimide and dicyclohexylcarbodiimide and subsequent removing the protecting groups with CF3CO2H. I-contg. pharmaceutical ***compns*** were reported.

=> d his

(FILE 'HOME' ENTERED AT 13:14:57 ON 13 SEP 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 13:15:17 ON 13 SEP 2003

L1 411 S HIS-PHE-ARG-TRP

L2 73 S HIS-D-PHE-ARG-TRP
L3 462 S L1 OR L2
L4 20 S COMPOSITION (P) L3
L5 9 DUPLICATE REMOVE L4 (11 DUPLICATES REMOVED)

=> s sexual (w) (response or dysfunction)
L6 17401 SEXUAL (W) (RESPONSE OR DYSFUNCTION)

=> s 16 (p) 13
L7 3 L6 (P) L3

=> duplicate remove 17
DUPLICATE PREFERENCE IS 'CAPLUS, BIOSIS'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L7
L8 3 DUPLICATE REMOVE L7 (0 DUPLICATES REMOVED)

=> d 18 1-3 ibib abs

L8 ANSWER 1 OF 3 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 2003:323715 BIOSIS
DOCUMENT NUMBER: PREV200300323715
TITLE: Compositions and methods for treatment of sexual
dysfunction.
AUTHOR(S): Blood, Christine H.; Shadiack, Annette M. (1); Bernstein,
Joanna K.; Herbert, Guy H.
CORPORATE SOURCE: (1) Somerset, NJ, USA USA
ASSIGNEE: Palatin Technologies, Inc., Cranbury, NJ, USA
PATENT INFORMATION: US 6579968 June 17, 2003
SOURCE: Official Gazette of the United States Patent and Trademark
Office Patents, (June 17 2003) Vol. 1271, No. 3, pp. No
Pagination. <http://www.uspto.gov/web/menu/patdata.html>.
e-file.
ISSN: 0098-1133.

DOCUMENT TYPE: Patent
LANGUAGE: English

AB Compositions and methods are provided for treatment of ***sexual***
dysfunction in mammals, including male ***sexual***
dysfunction, such as erectile dysfunction, and female
sexual ***dysfunction***. In one embodiment, a peptide-based
composition including the peptide sequence Ac-Nle-cyclo(-Asp- ***His***
- ***Phe*** - ***Arg*** - ***Trp*** -Lys)-OH is
administered. Methods of administration include injection, oral, nasal and
mucosal administration.

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:595493 CAPLUS
DOCUMENT NUMBER: 137:145614
TITLE: Pharmaceutical compositions containing a peptide for
treatment of sexual dysfunction
INVENTOR(S): Blood, Christine H.; Shadiack, Annette M.; Bernstein,
Joanna K.; Herbert, Guy H.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 20 pp., Cont.-in-part of U.S.
Ser. No. 606,501.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002107182	A1	20020808	US 2002-40547	20020104
US 6579968	B1	20030617	US 2000-606501	20000628

PRIORITY APPLN. INFO.:
US 1999-142346P P 19990629
US 2000-194987P P 20000405
US 2000-606501 A2 20000628

AB Compns. and methods are provided for treatment of ***sexual***
dysfunction in mammals, including male ***sexual***
dysfunction, such as erectile dysfunction, and female
sexual ***dysfunction***. In one embodiment, a peptide-based
compn. including the peptide sequence Ac-Nle-cyclo(-Asp- ***His*** -
Phe - ***Arg*** - ***Trp*** -Lys)-OH (I) is
administered. Methods of administration include injection, oral, nasal
and mucosal administration. I was dissolved in a 50 mM citrate, pH
approx. 6.0, at a concn. of .825 mg per mL to obtain a nasal soln. Nasal

administration of I at a concn. of 25 .mu.k/kg induced 100% penile erection in rats for 2 times in 30 min.

L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:12284 CAPLUS

DOCUMENT NUMBER: 134:76409

TITLE: Compositions and methods for treatment of sexual dysfunction

INVENTOR(S): Blood, Christine H.; Shadiack, Annette M.; Bernstein, Joanna K.; Herbert, Guy W.

PATENT ASSIGNEE(S): Palatin Technologies Inc., USA

SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000224	A1	20010104	WO 2000-US18217	20000629
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6579968	B1	20030617	US 2000-606501	20000628
BR 2000012200	A	20020326	BR 2000-12200	20000629
EP 1196184	A1	20020417	EP 2000-950283	20000629
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2003503357	T2	20030128	JP 2001-505933	20000629

PRIORITY APPLN. INFO.:

US 1999-142346P P 19990629
US 2000-194987P P 20000405
US 2000-606501 A 20000628
WO 2000-US18217 W 20000629

AB Compns. and methods are provided for the treatment of ***sexual***
dysfunctions in mammals, such as erectile dysfunction and female
sexual ***dysfunction***. In one embodiment, a peptide-based
compn. including the peptide sequence Ac-Nle-cyclo(-Asp- ***His*** -
D - ***Phe*** - ***Arg*** - ***Trp*** -Lys)-OH is
administered. Methods of administration include injection, oral, nasal
and mucosal administration.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s melanocortin receptor specific peptide

5 FILES SEARCHED...

L9 1 MELANOCORTIN RECEPTOR SPECIFIC PEPTIDE

=> s alpha-MSH

L10 13509 ALPHA-MSH

=> s l10 (p) (fragment or analog)

L11 1852 L10 (P) (FRAGMENT OR ANALOG)

=> s (l9 or l11) (p) l6

L12 2 (L9 OR L11) (P) L6

=> duplicate remove l12

PROCESSING COMPLETED FOR L12

L13 2 DUPLICATE REMOVE L12 (0 DUPLICATES REMOVED)

=> d l13 1-2 ibib abs

L13 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:58220 CAPLUS

DOCUMENT NUMBER: 138:117676

TITLE: Linear and cyclic melanocortin receptor-specific peptides, and therapeutic use

INVENTOR(S): Sharma, Shubh D.; Shadiack, Annette M.; Yang, Wei; Rajpurohit, Ramesh

PATENT ASSIGNEE(S): Palatin Technologies, Inc., USA
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003006620	A2	20030123	WO 2002-US22196	20020711
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2001-304836P P 20010711

OTHER SOURCE(S): MARPAT 138:117676

AB Linear and cyclic peptides are provided which are specific to melanocortin receptors and which exhibit agonist, antagonist, or mixed agonist-antagonist activity. The peptides of the invention may be used to treat e.g. erectile dysfunction and eating disorders.

L13 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:604743 CAPLUS

TITLE: PT-141: a melanocortin agonist for the treatment of sexual dysfunction

AUTHOR(S): Molinoff, P. B.; Shadiack, A. M.; Earle, D.; Diamond, L. E.; Quon, C. Y.

CORPORATE SOURCE: Palatin Technologies, Inc., Cranbury, NJ, 08512, USA

SOURCE: Annals of the New York Academy of Sciences (2003), 994(Melanocortin System), 96-102

CODEN: ANYAA9; ISSN: 0077-8923

PUBLISHER: New York Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

AB PT-141, a synthetic peptide ***analog*** of . ***alpha*** .-
MSH, is an agonist at melanocortin receptors including the MC3R and MC4R, which are expressed primarily in the central nervous system. Administration of PT-141 to rats and nonhuman primates results in penile erections. Systemic administration of PT-141 to rats activates neurons in the hypothalamus as shown by an increase in c-Fos immunoreactivity. Neurons in the same region of the central nervous system take up pseudorabies virus injected into the corpus cavernosum of the rat penis. Administration of PT-141 to normal men and to patients with erectile dysfunction resulted in a rapid dose-dependent increase in erectile activity. The results suggest that PT-141 holds promise as a new treatment for ***sexual*** ***dysfunction***.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 13:14:57 ON 13 SEP 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 13:15:17 ON 13 SEP 2003

L1 411 S HIS-PHE-ARG-TRP
L2 73 S HIS-D-PHE-ARG-TRP
L3 462 S L1 OR L2
L4 20 S COMPOSITION (P) L3
L5 9 DUPLICATE REMOVE L4 (11 DUPLICATES REMOVED)
L6 17401 S SEXUAL (W) (RESPONSE OR DYSFUNCTION)
L7 3 S L6 (P) L3
L8 3 DUPLICATE REMOVE L7 (0 DUPLICATES REMOVED)
L9 1 S MELANOCORTIN RECEPTOR SPECIFIC PEPTIDE
L10 13509 S ALPHA-MSH
L11 1852 S L10 (P) (FRAGMENT OR ANALOG)
L12 2 S (L9 OR L11) (P) L6
L13 2 DUPLICATE REMOVE L12 (0 DUPLICATES REMOVED)

```

=> s blood christine/au
L14      8 BLOOD CHRISTINE/AU

=> s shadiack annette/au
L15      2 SHADIACK ANNETTE/AU

=> s berstein joanna/au
L16      0 BERSTEIN JOANNA/AU

=> s l14 or l15
L17     10 L14 OR L15

=> s l3 and l17
L18      0 L3 AND L17

=> d his

```

(FILE 'HOME' ENTERED AT 13:14:57 ON 13 SEP 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 13:15:17 ON 13 SEP 2003

```

L1      411 S HIS-PHE-ARG-TRP
L2      73 S HIS-D-PHE-ARG-TRP
L3     462 S L1 OR L2
L4      20 S COMPOSITION (P) L3
L5       9 DUPLICATE REMOVE L4 (11 DUPLICATES REMOVED)
L6    17401 S SEXUAL (W) (RESPONSE OR DYSFUNCTION)
L7       3 S L6 (P) L3
L8       3 DUPLICATE REMOVE L7 (0 DUPLICATES REMOVED)
L9       1 S MELANOCORTIN RECEPTOR SPECIFIC PEPTIDE
L10    13509 S ALPHA-MSH
L11    1852 S L10 (P) (FRAGMENT OR ANALOG)
L12       2 S (L9 OR L11) (P) L6
L13       2 DUPLICATE REMOVE L12 (0 DUPLICATES REMOVED)
L14       8 S BLOOD CHRISTINE/AU
L15       2 S SHADIACK ANNETTE/AU
L16       0 S BERSTEIN JOANNA/AU
L17      10 S L14 OR L15
L18       0 S L3 AND L17

```

=> log y		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	78.35	78.56
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.21	-5.21

STN INTERNATIONAL LOGOFF AT 13:24:23 ON 13 SEP 2003